Ad Code: 57786

C ompared with other oncogenic drivers, ERBB2 (also known as HER2) tends to have poor prognosis in patients with advanced NSCLC, according to researchers, who noted that the treatment for ERBB2-altered NSCLC has been studied for...

A blood-based biomarker panel combined with the Prostate, Lung, Colorectal, and Ovarian (PLCO) risk model (PLCOm2012) can identify individuals at high risk for lethal lung cancer, according to a study published in the Journal of...

For older patients with advanced NSCLC, treatment with immune checkpoint inhibitors (ICIs) may be a safe and effective option, according to a study published in Respiratory Investigation. Researchers conducted a retrospective...